Northwire Canada EditionSaturday, July 11, 2026
Northwire
GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0%
Production / Operations

Rapid Dose talks up IP wins, market expansion

DOSE · Price

Executive Summary

  • Rapid Dose Therapeutics provided a strategic update highlighting operational resilience, global expansion, and key milestones achieved since the beginning of 2026.
  • The company secured a significant patent in India for its nicotine bilayer oral film and launched its QuickStrip medical cannabis product in Brazil following ANVISA regulatory approval.
  • The company listed on the OTCQB Venture Market under the symbol RDTCF to enhance U.S. investor access and liquidity.

Key Details

  • Intellectual Property: Secured Indian patent (IN 582202) for nicotine bilayer oral film in partnership with Aavishkar Oral Strips Pvt. Ltd., strengthening IP protection across 158 jurisdictions under the Patent Cooperation Treaty.
  • Tobacco Collaboration: Entered the fourth year of collaboration with a major global tobacco partner; continuing pharmacokinetic (PK) trials aim to demonstrate that the QuickStrip nicotine formulation replicates the rapid absorption profile of traditional cigarettes.
  • Brazil Expansion: Launched QuickStrip medical cannabis product in Brazil after receiving regulatory approval from ANVISA, accessing a major Latin American pharmaceutical market.
  • U.S. Market Access: Listed on the OTCQB Venture Market under the ticker symbol RDTCF to improve liquidity and market visibility.
  • Clinical Research: Advanced a CBD bioavailability study in collaboration with the University of Regina and the University of Saskatchewan; supported by NFL research funding, with data collected from over 60% of participants.
  • 2026 Strategic Priorities: Focus on expanding into regulated international markets via partnerships, strengthening distribution for natural health products, advancing clinical research, and scaling Canadian manufacturing capabilities for pharmaceutical-grade production.
  • Operational Resilience: Company states its business model is insulated from external disruptions, with no dependency on oil-linked inputs or global shipping constraints, and a cost structure primarily composed of stable, fixed components.

Notable Quotes

  • "Our momentum in 2026 reflects the strength of our strategy and the scalability of the QuickStrip platform... RDT is well insulated from current macroeconomic pressures and exceptionally well positioned to deliver sustainable, long-term value for our shareholders." — Mark Upsdell, Chief Executive Officer
Read the original news release →

More from Rapid Dose Therapeutics Corp